Monthly Archives: January 2026

Love Three: How THREE International Is Building Purpose Into the Foundation of Growth

In today’s direct selling landscape, growth alone is no longer the sole measure of success. Increasingly, the most respected companies are those that pair performance with purpose — building opportunities that benefit entrepreneurs while also creating true, meaningful impact.
At THREE International, this philosophy came to life in 2025 with the launch of Love Three.
Love Three represents THREE’s commitment to integrating purpose into the foundation of its business.
Designed as a long-term platform rather than a one-time initiative, Love Three reflects a belief shared by many modern industry leaders: that sustainable growth, strong culture, and meaningful impact are deeply connected.
What Is Love Three?
Love Three is a philanthropic initiative and purpose-driven movement rooted in generosity. Its mission is to give back to the world in meaningful ways, wherever the THREE community operates. Love Three envisions a world where children feel safe, seen, and supported — and where they have lasting hope for a brighter future.
Built to align naturally with THREE’s values and culture, Love Three provides a framework for collective impact. Rather than existing outside the business, it strengthens the sense of connection within the field and reinforces the company’s commitment to leadership with intention. At an industry level, this reflects

Read more...

Zinzino Preliminary Sales Report 2025

Zinzino group revenue increased 46% in Q4 and total revenue for the full year 2025 increased 51%, compared with the previous year.
The revenue in December for Zinzino‘s sales markets increased by 35% and amounted to SEK 334.4 (246.9) million. Faun Pharma’s external sales decreased and amounted to SEK 2.9 (5.8) million. Overall, the Group increased revenues by 33% to SEK 337.3 (252.7) million compared with the previous year.
Revenue in Zinzino’s sales markets increased by 50% in the fourth quarter of 2025 compared with the same period last year and amounted to SEK 1,032.3 (690.3) million. Total revenues in the Group increased by 46% in the fourth quarter and amounted to SEK 1,042.4 (713.5) million.
Accumulated revenue for January – December 2025 increased by 51% to SEK 3,344.5 (2,207.8) million.
Revenues were distributed as follows:

Regions, mSEK
25-Dec
24-Dec
Change
Q4 2025
Q4 2024
Change
YTD 2025
YTD 2024
Change

The Nordics
31.4
29.6
6%
98.4
88.0
12%
332.5
302.0
10%

Central Europe
102.9
78.1
32%
337.9
202.3
67%
995.4
596.7
67%

East Europe
36.3
34.5
5%
122.0
120.6
1%
398.0
400.4
-1%

South & West Europe
53.7
49.7
8%
167.8
131.9
27%
565.8
396.4
43%

The Baltics
18.0
12.0
50%
48.3
38.2
26%
133.5
107.6
24%

North America
52.0
21.1
146%
163.8
66.3
147%
545.7
200.5
172%

Asia-Pacific
37.4
20.2
85%
86.2
37.1
132%
299.4
84.6
254%

Africa
2.7
1.7
59%
7.8
5.9
32%
23.8
16.8
42%

Zinzino
334.4
246.9
35%
1,032.3
690.3
50%
3,294.1
2,105.0
56%

Faun Pharma
2.9
5.8
-50%
10.1
23.2
-57%
50.4
102.8
-51%

Zinzino Group
337.3
252.7
33%
1,042.4
713.5
46%
3,344.5
2,207.8
51%

Countries in regions:

The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden
Central Europe: Austria, Germany, Switzerland
East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania
South & West Europe: Cyprus, France, Greece, Italy, Luxembourg, Malta, Netherlands, Slovenia, Spain, United Kingdom, Belgium, Ireland, Serbia, Turkey, Canary Islands
The Baltics: Estonia, Latvia, Lithuania
North America: Canada, USA, Mexico
Asia-Pacific: Australia, New Zealand, Hong

Read more...